ADVA posts quarterly revenues of EUR 144.3 million for Q3 2019
24.10.2019 08:00:00 EEST | Business Wire | Press release
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q3 2019 ended on September 30, 2019. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191023005917/en/
Uli Dopfer, CFO, ADVA (Photo: Business Wire)
Q3 2019 financial summary1
|
(in thousands of EUR) |
Q3 |
Q3 |
Change |
Q2 |
Change |
|
|||||||
|
|
2019 |
2018 |
|
2019 |
|
|
|||||||
|
|
|
||||||||||||
|
Revenues |
144,310 |
126,178 |
14.4% |
133,216 |
8.3% |
|
|||||||
|
Pro forma gross profit |
49,086 |
47,304 |
3.8% |
46,513 |
5.5% |
|
|||||||
|
in % of revenues |
34.0% |
37.5% |
-3.5pp |
34.9% |
-0.9pp |
|
|||||||
|
Pro forma operating income |
7,393 |
6,776 |
9.1% |
4,337 |
70.5% |
|
|||||||
|
in % of revenues |
5.1% |
5.4% |
-0.3pp |
3.3% |
1.8pp |
|
|||||||
|
Operating income (loss) |
3,2002 |
4,994 |
-35.9% |
2,497 |
28.2% |
|
|||||||
|
Net income |
2,190 |
3,908 |
-44.0% |
1,297 |
68.9% |
|
|||||||
|
|
|||||||||||||
|
(in thousands of EUR) |
Sep. 30 2019 |
Sep. 30 2018 |
Change |
Jun. 30 2019 |
Change |
|
|||||||
|
Cash and cash equivalents |
38,396 |
53,949 |
-28.8% |
48,275 |
-20.5% |
|
|||||||
|
Net debt3 |
74,873 |
38,656 |
93.7% |
68,117 |
9.9% |
|
|||||||
1 Potential differences due to rounding
2 Including EUR 2.5 million one-off expenses
3 Q3 and Q2 2019 include lease liabilities of EUR 36.2 million due to first-time adoption of IFRS 16
Q3 2019 IFRS financial results
Revenues for Q3 2019 increased by 8.3% to EUR 144.3 million from EUR 133.2 million in Q2 2019 and grew by 14.4% from EUR 126.2 million in the same year-ago period. Revenues for Q3 2019 were in the upper range of the guidance corridor the company provided on July 25, 2019, of between EUR 135 million and EUR 145 million.
Pro forma operating income for Q3 2019 was EUR 7.4 million (5.1% of revenues), compared to EUR 4.3 million (3.3% of revenues) in Q2 2019 and compared to a pro forma operating income of EUR 6.8 million (5.4% of revenues) in the same year-ago period. Pro forma operating income for Q3 2019 was also at the upper end of the company’s guidance range of between 3% and 6% of revenues.
Operating income for Q3 2019 of EUR 3.2 million increased from EUR 2.5 million reported for Q2 2019 and decreased compared to EUR 5.0 million in the same year-ago quarter. This is mainly due to tariffs on China-made products in the US market and the strength of the US dollar.
Net income for Q3 2019 increased substantially by 68.9% to EUR 2.2 million from EUR 1.3 million in Q2 2019; however, it declined significantly from EUR 3.9 million in Q3 2018.
At quarter-end, the company’s cash and cash equivalents totaled EUR 38.4 million, representing a decrease of 20.5% compared to EUR 48.3 million at the end of Q2 2019. The company built up inventories and thus working capital in the past quarter to reduce the negative impact of import duties, which led to a reduction in cash and cash equivalents.
The company’s net debt increased by EUR 6.8 million to EUR 74.9 million from EUR 68.1 million at the end of Q2 2019.
Net working capital at quarter-end was EUR 137.8 million compared to EUR 127.6 million at the end of Q2 2019.
“In the third quarter of the fiscal year, our revenues continued to develop very positively, and we are satisfied with the overall order entry,” commented Uli Dopfer, CFO, ADVA. “Both of our two key metrics were at the upper end of our guidance range, and year-over-year we increased revenues significantly by 14.4%. Somewhat challenging, on the other hand, are the negative effects of US trade policy on our business. As such, we’ve taken several measures to counteract the impact of this trade conflict. These include the relocation of production from China, proactive material purchasing and rapid transfer of pre-engineered subsystems, as well as tightening the control of operational costs. These measures are partly associated with one-time costs but will sustainably support us in terms of the positive development of our profitability.”
“We’ve made significant progress across all of our strategic product groups in Q3. As a result, customer demand for our technology continues to accelerate,” said Brian Protiva, CEO, ADVA. “Our new FSP 3000 TeraFlex™ terminal is truly industry-leading. It provides open, scalable and programmable optical transmission technology that delivers the lowest cost per bit. With these features, it's no surprise that this product is testing so strongly with our customers. Our FSP 150 packet edge solutions combined with our Ensemble software suite is also drawing strong customer reaction and is playing a pivotal role in the development of new open networking concepts such as edge computing. What’s more, our NFV software continues to grow in strength and customer wins are rapidly accelerating. And last but not least, the positive revenue development of our Oscilloquartz synchronization solutions continues to gather momentum. So much so, we expect to exceed our good 2018 results in this area in the current financial year.”
Q4 2019 financial outlook
For Q4 2019, ADVA expects revenues to be in the range of EUR 142 million and EUR 152 million and a pro forma operating income of between 5% and 7% of revenues.
The company will publish its financial results for Q4 and the full fiscal year 2019 on February 20, 2020.
Conference call details
ADVA will hold a conference call for analysts and investors today, October 24, 2019, to discuss these results and management’s outlook. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CET (9:00 a.m. EDT). A question and answer session will follow management presentations.
To participate, please dial the appropriate number at least five minutes before the start time and ask for the ADVA conference call.
International number: +49 69 201 744 210
US number: +1 877 423 08 30
Pin code: 417 32 288#
A corresponding presentation is available on ADVA’s website: https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete quarterly statement 9M 2019 (January – September) is available as a PDF here: https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here: https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191023005917/en/
Contact information
For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
